PDF(Pubmed)
Abstract：
BACKGROUND: Sepsis remains a leading cause of death worldwide. In this context, heparin-binding protein (HBP) has emerged as a possible biomarker, drawing significant attention for its diagnostic and prognostic usefulness in septic patients. Despite this advancement, the literature yields conflicting results. This study is intended to critically evaluate the diagnostic and prognostic value of HBP in critically ill septic patients.
METHODS: We searched multiple databases, including PubMed, SCOPUS, Web of Science, and EBSCO, to identify relevant studies on April 27, 2023. We included studies investigating sepsis or its severe outcomes that reported HBP levels and the required data to create 2 × 2 tables. We used R version 4.2.2 and R Studio to analyze the pooled diagnostic accuracy outcomes. The diagmeta package was utilized to calculate the optimum cutoff value.
RESULTS: In our meta-analysis, we incorporated 28 studies including 5508 patients. The analysis revealed that HBP has a sensitivity of 0.71 (95% CI: 0.60; 0.79) and a specificity of 0.68 (95% CI: 0.51; 0.81) in diagnosing sepsis, respectively. HBP demonstrated moderate prognostic accuracy for mortality at a cutoff value of 161.415 ng/mL, with a sensitivity and specificity of 72%, and for severe sepsis outcomes at a cutoff value of 58.907 ng/mL, with a sensitivity and specificity of 71%.
CONCLUSIONS: Our findings indicate a relatively moderate diagnostic and prognostic accuracy of HBP for sepsis. Future studies are required to verify the accuracy of HBP as a biomarker for sepsis.
METHODS: We searched multiple databases, including PubMed, SCOPUS, Web of Science, and EBSCO, to identify relevant studies on April 27, 2023. We included studies investigating sepsis or its severe outcomes that reported HBP levels and the required data to create 2 × 2 tables. We used R version 4.2.2 and R Studio to analyze the pooled diagnostic accuracy outcomes. The diagmeta package was utilized to calculate the optimum cutoff value.
RESULTS: In our meta-analysis, we incorporated 28 studies including 5508 patients. The analysis revealed that HBP has a sensitivity of 0.71 (95% CI: 0.60; 0.79) and a specificity of 0.68 (95% CI: 0.51; 0.81) in diagnosing sepsis, respectively. HBP demonstrated moderate prognostic accuracy for mortality at a cutoff value of 161.415 ng/mL, with a sensitivity and specificity of 72%, and for severe sepsis outcomes at a cutoff value of 58.907 ng/mL, with a sensitivity and specificity of 71%.
CONCLUSIONS: Our findings indicate a relatively moderate diagnostic and prognostic accuracy of HBP for sepsis. Future studies are required to verify the accuracy of HBP as a biomarker for sepsis.
摘要：
背景：脓毒症仍然是全球死亡的主要原因。在这种情况下，肝素结合蛋白（HBP）已经成为一种可能的生物标志物，引起人们对脓毒症患者的诊断和预后有用性的关注。尽管有这样的进步,文献产生了相互矛盾的结果。本研究旨在严格评估HBP在危重脓毒症患者中的诊断和预后价值。
方法：我们搜索了多个数据库，包括PubMed,Scopus,WebofScience,和EBSCO,于2023年4月27日确定相关研究。我们纳入了调查脓毒症或其严重结局的研究，这些研究报告了HBP水平和创建2×2表格所需的数据。我们使用R版本4.2.2和RStudio分析汇总的诊断准确性结果。使用diagmeta软件包来计算最佳截止值。
结果：在我们的荟萃分析中，我们纳入了28项研究,包括5508例患者.分析显示，HBP在诊断败血症方面的敏感性为0.71（95％CI：0.60;0.79），特异性为0.68（95％CI：0.51;0.81）。分别。HBP在161.415ng/mL的临界值时显示出中等的死亡率预后准确性，灵敏度和特异度为72%,对于严重脓毒症的结果，截止值为58.907ng/mL，敏感性和特异性为71%。
结论：我们的研究结果表明HBP对脓毒症的诊断和预后准确性相对中等。未来的研究需要验证HBP作为脓毒症生物标志物的准确性。
方法：我们搜索了多个数据库，包括PubMed,Scopus,WebofScience,和EBSCO,于2023年4月27日确定相关研究。我们纳入了调查脓毒症或其严重结局的研究，这些研究报告了HBP水平和创建2×2表格所需的数据。我们使用R版本4.2.2和RStudio分析汇总的诊断准确性结果。使用diagmeta软件包来计算最佳截止值。
结果：在我们的荟萃分析中，我们纳入了28项研究,包括5508例患者.分析显示，HBP在诊断败血症方面的敏感性为0.71（95％CI：0.60;0.79），特异性为0.68（95％CI：0.51;0.81）。分别。HBP在161.415ng/mL的临界值时显示出中等的死亡率预后准确性，灵敏度和特异度为72%,对于严重脓毒症的结果，截止值为58.907ng/mL，敏感性和特异性为71%。
结论：我们的研究结果表明HBP对脓毒症的诊断和预后准确性相对中等。未来的研究需要验证HBP作为脓毒症生物标志物的准确性。
